All Episodes
GHAPPcast — 162 episodes
Podcast: How to Screen and Diagnose Cholestatic Liver Diseases
GHAPPcast: Recognizing and Managing Overt Hepatic Encephalopathy
FAQ: Counseling Patients on Overt Hepatic Encephalopathy
FAQ: Identifying & Diagnosing Overt Hepatic Encephalopathy
Subgroup Analysis: Differences in Maintenance Dosing For UC and CD
Medication Review: Efficacy & Safety of Risankizumab in Patients with Moderate to Severely Active UC
Med Review: SEQUENCE Trial: Risankizumab vs Ustekinumab in Anti-TNF-Refractory Crohn’s Disease
FAQ: QUASAR Long Term Extension Interim Analysis
Medication Review: Guselkumab IV vs SC Formulation
FAQ: Recognizing OHE Risk in Patients with Chronic Liver Disease
FAQ: Phase 3 GALAXI 2 & 3: Extraintestinal Manifestations In Moderate to Severe Crohn’s Disease
Medication Review: Monotherapy vs. Combination Therapy: Relevance in IBD Treatment Strategy
Medication Review: Stable PK Supporting Continuous Inflammatory Control
Journal Club: ASTRO Phase 3 Study: Efficacy and Safety of SC Guselkumab
Journal Club: Benefit–Risk Profile of Upadacitinib in Patient’s With Moderate to Severe UC and CD
Podcast: How Do You Best Support Patients Getting Started on New MASH Treatments?
Podcast: Best Practices For Patient Identification
Podcast: SubQ Solutions: Induction and Maintenance in Moderately to Severely Active CD and UC
FAQ: Treat Through VS Randomized Withdrawal Design: What's The Difference?
Medication Review: GALAXI & GRAVITI Clinical Trials & LTE Data
Podcast: Inflammation Intersection: A Rheum-Gi Dialogue
Journal Club: Risankizumab Long-Term Efficacy in Crohn’s Disease: FORTIFY Extension Results
Podcast: Upadacitinib FDA Label Update: What Clinicians Need to Know
FAQ: Biomarkers: The Non-Invasive Future of HCC Detection
FAQ: Approved Systemic Therapy in Upadacitinib’s Expanded UC and CD Indications
FAQ: What Does Clinically Inadvisable Mean in Upadacitinib’s Expanded UC and CD Indications?
FAQ: How Do You Balance Systemic and Liver Directed Therapies in Patients With MASH?
FAQ: What is the Relevance of Assessing Alcohol Consumption in Patients With MASH?
Medication Review: Resmetirom: Thyroid Hormone Receptor-β Agonism in MASH Treatment
APP Roundtable: Approach To Starting Treatments in Patients With CHB
APP Roundtable: Navigating Difficult Conversations in CHB
APP Roundtable: Addressing Co-Morbidities in CHB
FAQ: What Role Do NITs Play in Risk Stratification & Patient Selection—& Balancing Patient History?
Journal Club: Review of Focused Recommendations for the Management of MASLD
Medication Review: Resmetirom: Core Efficacy Data and Patient Selection Considerations
FAQ: What Are The Functional And Prognostic Differences Between Fibrosis F3 And F4 Patients?
The Conversation That Matters: Talking to Patients About Obesity and IMIDs
From Insight to Action: Practical Strategies to Improve Outcomes in Patients with Obesity and IMIDs
GHAPPcast: Women of Childbearing Age With IBD
The Hidden Costs: Obesity’s Role in Suboptimal Outcomes and Healthcare Burden in IMIDs
FAQ: How Do You Explain Remission To A Patient?
GHAPPcast: Mental and Sexual Health Concerns & How To Address Them For Your IBD Patient
Obesity and IMIDs: Unpacking the Epidemic and Its Far-Reaching Impacts
APP Insight: How Do You Develop a Treatment Plan for IBS-C? What Are Some Considerations?
GHAPPcast: IBS-C Therapies Explained: Helping Patients Understand Their Options
GHAPPcast: Smarter Surveillance: The Rise of Algorithms like GALAD and Their Path to Practice
FAQ: What Is the Importance of Biomarkers Such as Fecal Calprotectin and CRP?
FAQ: What Are the Next Steps When a Patient Still Has Active Disease When Taking Advanced Therapy?
APP Roundtable: Community Resources and Support Systems for CHB
APP Insight: Conducting Meaningful Conversations to Assess Therapy Impact
GHAPPcast: Decoding Diagnostics: Why Biomarker Development Phases Are Your Clinical Ally
GHAPPcast: Explaining IBS-C: Diagnosis and Communication That Builds Confidence
APP Insight: Evaluating Time to Response and Treatment Effectiveness
APP Insight: Why Is It Important to Let Patients Know There Are Different Options for Treatment?
Empowering PBC Patients: APPs’ Role in Education and Support
GHAPPcast: Payer Tutorial
APP Roundtable: Navigating Treatment Guidelines With CHB
APP Roundtable: Patient-Centric Care Approaches in PBC
APP Roundtable: Addressing Mental Health in Patients With PBC
GHAPPcast: Setting the Standard in Biomarker Validation: EDRN Example & Lessons from Liver Cancer
GHAPPcast: Navigating Difficult Conversations: Discussing prognosis and lifelong care in PBC
GHAPPcast: Collaborating Across Specialties: How APPs Can Work with Hepatologists & Other Providers in PBC Care
GHAPPcast: Managing PBC Symptoms in the Real World: Practical Tips for APPs
FAQ: What Is the Difference Between CIC and IBS-C?
GHAPPcast: Lifestyle and Nutrition Interventions for Constipation
APP Insight: Discussing Exercise as a Complement to IBS-C Treatment
GHAPPcast: Mental Health Issues and Symptoms Related to IBS-C
FAQ: What Is the Significance of Alarm Symptoms Including Pathophysiology?
APP Roundtable: Future Directions in CHB Research
APP Roundtable: Navigating Treatment Guidelines in CHB
APP Insight: Provide Diagnostic Tips for IBS-C
APP Insight: Using the Bristol Stool Scale to Measure Response to Treatment
APP Roundtable: Challenges in Diagnosing CHB
APP Roundtable: Future Directions in PBC Research
APP Roundtable: Multidisciplinary Care Models in PBC Management
APP Roundtable: PBC Patient Perspectives & Advocacy
FAQ: What Are the Main Causes of IBS, and How Does the Disease Progress Over Time?
KOL Conversation: Setting Expectations When Initiating New Therapy
KOL Conversation: Diagnosing IBS With Confidence
KOL Conversation: Diagnosing EPI and Managing With The Appropriate PERT Dosing
KOL Conversation: Implementing the IBS Guidelines
GHAPPcast: The Clinical Utility of Guselkumab in CD
GHAPPcast: Not Responding to UDCA in the First Few Months, Need to Move on to Second-Line Therapy
GHAPPcast: Need for Earlier Evaluation of UDCA Response, Need for Earlier Consideration of Second-Line Therapy
GHAPPcast: Building a Sense of Urgency for PBC Patient Evaluation/Monitoring
GHAPPcast: Importance of Understanding Impact on Disease Outcomes: Progression to Fibrosis and Cirrhosis
GHAPPcast: Need for Clinicians to Better Understand The "Area Under the Curve" in Non-Response to UDCA
GHAPPcast: Unable to Differentiate/Identify Between Slow & Fast Progressors - Need to Manage More Aggressively
GHAPPcast: Better Understanding of PBC Patients Overall Liver Health and Managing Patients Holistically
GHAPPcast: Biomarkers Beyond ALP to Monitor for Measuring PBC UDCA Response to Therapy and Disease Progression
Journal Club: Week 48 Efficacy of Guselkumab vs. Ustekinumab in Crohn’s Disease: Insights from GALAXI 2 & 3
GHAPPcast: Simplifying Access: Evolving Drug Distribution Channels
GHAPPcast: Simplifying Access: Prior Authorization Part 2
GHAPPcast: Simplifying Access: Prior Authorization Part 1
Journal Club: Efficacy & Safety of Subcutaneous Guselkumab: 48-Week Results from the Phase 3 GRAVITI Study
GHAPPcast: The Clinical Utility of Guselkumab in UC
KOL: What Are the Most Critical Updates in Cirrhosis Research That Clinicians Should Be Aware Of?
KOL: How Can Healthcare Professionals Improve Patient Outcomes in Those with Cirrhosis?
Journal Club: Efficacy and Safety of Guselkumab in Ulcerative Colitis: Phase 3 QUASAR Maintenance Study Results
FAQ: How does the guselkumab data align with the STRIDE II guidelines?
Medication Review: What are guselkumab's other FDA indications and how might that affect patient care?
KOL Interview: Can You Discuss Any Recent Breakthroughs in the Management of Cirrhosis?
FAQ: What should patients know about living with cirrhosis?
FAQ: What are predictive risk factors for disease severity in CD and UC?
FAQ: What lifestyle changes are essential for managing cirrhosis effectively?
Journal Club: Guselkumab Efficacy & Safety in Moderate to Severe CD-GALAXI 2 & 3 Results
FAQ: How Can You Support a Shared Decision-Making Process With the Patient?
Medication Review: What is the efficacy of guselkumab in ulcerative colitis and Crohn's disease?
FAQ: How can physicians better care for patients with cirrhosis?
Medication Review: What is the safety profile of guselkumab in ulcerative colitis and Crohn's disease?
Journal Club: Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study
GHAPPcast Part 3: Provider & Patient Support
FAQ: Is there a correlation of myeloid cells expressing CD64 and endoscopy disease severity?
GHAPPcast Part 2: Diagnosis and Management
FAQ: Why is binding CD64+ important when discussing IL23 directed therapy?
GHAPPcast Part 1: Understanding Chronic Liver Disease and Cirrhosis
Medication Review: How is guselkumab dosed in IBD?
GHAPPcast: CD64+ Binding: Description, Relevance, and Potential Clinical Implications
FAQ: Provide immunologic rationale for IL23 directed therapy in IBD(+ general overview of Guselkumab MOA)
Journal Club: Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis
Medication Review: What is non-responder imputation and how is it utilized in clinical trials?
FAQ: What is the role of IL23/IL17 axis in IBD
FAQ: Describe the IL23/IL17 axis
GHAPPcast: The IL23/IL17 Cascade and Implications in the Pathogenesis of IBD
Medication Review: Describe the mechanism of action of guselkumab
FAQ: Define, compare, and contrast humoral and cell-mediated immunity.
GHAPPcast: CSID in Adults: Clinical Pearls & the Patient Journey
GHAPP PBC Podcast Series Part 2: New Therapeutics In The PBC Space
GHAPP PBC Podcast Series Part 1: Prevalence, Awareness and Identification of PBC
GHAPP PBC Podcast Series Part 3: The Key Highlights of PBC at the GHAPP Conference 2024
KOL Conversation: A New Treatment Option
KOL Conversation: New & Emerging Treatment Considerations for PBC & PBC Pruritus
Journal Club: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
FAQ: What is MASH?
Medication Review Video Module: What is Resmetirom and how does it work to treat MASH?
FAQ: What are the consequences of NASH going untreated?
FAQ: How is MASH severity staged? What would an ideal MASH NIT algorithm look like?
Medication Review: What is the clinical profile of Resmetirom, including dosing schedules?
GHAPPcast: Recognizing the Severity of MASH
FAQ: Best practices to accelerate the time to finding the right therapy for your patients with IBS-C?
GHAPPcast: Navigating IBS: Pathophysiology, Neuromodulators, and Patient-Centered Care
FAQ: What does it mean for a biosimilar to be interchangeable and why is that important?
FAQ: What resources do you use to understand the latest approaches to managing IBS-C patients?
FAQ: What are some best practices in determining clinically meaningful “response” to therapy for IBS-C patients?
GHAPPcast: Biosimilars and the Patient Perspective
GHAPPcast: Mastering IBS-C: Diagnostic Strategies, Differentiation, and Management.
FAQ: What is the Difference Between Biosimilars and Generics?
FAQ: What Role Does a New Mechanism of Action Play in Your Prescribing Decisions of IBS-C Therapy?
GHAPPcast: Biosimilars Unveiled: Empowering APPs for Better Patient Conversations
CLDF/GHAPP Roundtable Podcast Series: MASH with Nadege Gunn, MD, Elizabeth Goacher, PA, and Ann Moore, FNP
Discussing Biosimilars With Patients
The Nocebo Effect
The Practical Use of Biosimilars in Gastroenterology APP Practice
The Practical Use of Biosimilars in Rheumatology APP Practice
The Benefits of Biosimilars
Managed Care and Biosimilars
Interchangeability & Switching of Biosimilars
Biosimilar Extrapolation
The Difference Between Biosimilars & Generic Drugs
The Regulatory Pathway to Biosimilar Approval
Development of Biosimilars
Biosimilars Series: What Are Biosimilars?